Abstract 50P
Background
Epithelial cells express MUC1, with its oncogenic subunit, MUC1-C, enriched on malignant cells. P-MUC1C-ALLO1 is an allogeneic MUC1-C targeting CAR-T produced from healthy donor T-cells via non-viral transposon-based integration to express a human scFv anti-MUC1-C CAR to produce a T stem cell memory-rich product. The Cas CLOVER™ gene editing system is used to ablate the TCR beta chain and partially knock out the beta-2 microglobulin gene to prevent graft vs host disease and attenuate host vs graft respectively. P-MUC1C-ALLO1 is available “off-the-shelf” and is being evaluated in a phase 1 clinical trial (NCT05239143) in advanced epithelial malignancy patients (pts).
Methods
The trial utilizes 3+3 dose escalation to test P-MUC1C-ALLO1 doses from 0.75 to 15 × 106 cells/kg and several lymphodepletion (LD) regimens that explore increasing doses of cyclophosphamide (cy) combined with fludarabine (flu). Objectives include defining Maximal Tolerated Dose, safety and efficacy.
Results
To date, 41 pts (median age 56 (29-73) years), median of 5 (1-20) prior therapies, received P-MUC1C-ALLO1 (0.75 × 106 – 6.0 × 106 cells/kg); two pts were retreated. No pt required bridging therapy; median time from enrollment to the start of protocol therapy was just 9 (2-20) days. Patients with the following malignancies have enrolled: breast (n=8), pancreatic (n=7), colorectal (n=12), uterine (n=2), ovarian (n=2), appendiceal (n=4), and other (n=6). Most adverse events (AEs) were LD or cancer related. The most common Grade ≥3 treatment emergent AEs were neutropenia (88%), leukopenia (47%), lymphopenia (33%), anemia (19%), thrombocytopenia (16%), and febrile neutropenia (12%). All grade treatment related AEs included CRS (16%), increased AST (12%), increased alkaline phosphatase (12%), and pyrexia (12%). No ICANS or GvHD were reported. Two patients who received 2 × 106 P-MUC1C-ALLO1 cells/kg following LD with cy 1000 mg/m2 and flu 30 mg/m2 × 3 days developed G3 CRS (DLT). No DLTs were reported in any other study arms.
Conclusions
P-MUC1C-ALLO1 is an “off-the-shelf” allogeneic CAR-T with a manageable toxicity profile in heavily pre-treated solid tumor patients. Updated safety and efficacy data will be presented at the conference.
Clinical trial identification
NCT05239143.
Legal entity responsible for the study
Poseida Therapeutics Inc.
Funding
Poseida Therapeutics.
Disclosure
D. Oh: Financial Interests, Personal, Advisory Board, Licensing fees relating to a patent on the use of T cell receptor sequencing as a predictive marker of immune-related adverse events with immunotherapy: Regents of the University of California; Financial Interests, Personal and Institutional, Local PI, Research support: Merck Sharp & Dohme, Nutcracker Therapeutics; Financial Interests, Institutional, Local PI, Research support: PACT Pharma, Poseida Therapeutics, TCR2 Therapeutics, Allogene Therapeutics; Financial Interests, Personal and Institutional, Local PI, Research support, travel & accommodations for Roche-sponsored research meeting: Roche/Genentech; Financial Interests, Personal, Other, Consulting: Revelation Partners; Non-Financial Interests, Institutional, Proprietary Information, Proprietary materials for laboratory experimentation: Nutcracker Therapeutics, 3T Biosciences. P. Vu, J.C. Baranda, J. Henry: Financial Interests, Institutional, Local PI: Poseida Therapeutics. I.I. Rodriguez Rivera: Financial Interests, Institutional, Local PI: Poseida Therapeutics. J.D. Eskew: Financial Interests, Personal, Full or part-time Employment: Poseida Therapeutics; Financial Interests, Personal, Stocks/Shares: Poseida Therapeutics. R. Belani, M. Martinez-Prieto, J. McCaigue, H. Namini, S. Haag, D. Bauer, C. Martin, C. Gregovics, A. Murphy, J. Coronella: Financial Interests, Personal, Full or part-time Employment: Poseida Therapeutics; Financial Interests, Personal, Stocks/Shares: Poseida Therapeutics . D.J. Shedlock: Financial Interests, Personal, Full or part-time Employment: Poseida Therapeutics ; Financial Interests, Personal, Stocks/Shares: Poseida Therapeutics; Financial Interests, Personal, Leadership Role: Poseida Therapeutics. E.E. Dumbrava: Financial Interests, Institutional, Other, Research/grant funding: Bayer HealthCare Pharmaceuticals, Immunocore Ltd, Amgen, Aileron Therapeutics, Compugen Ltd, Gilead, Bolt Therapeutics, Aprea Therapeutics, Bellicum, PMV Pharma, Triumvira, Seagen Inc., Mereo BioPharma 5 Inc., Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Mersana Therapeutics, Poseida, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: PMV Pharma; Financial Interests, Personal, Advisory Board: Bolt Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics.
Resources from the same session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session